Rama Ayash | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Dr. Rama Ayash | Medicine and Health Sciences | Best Researcher Award

Damascus University | Syria

Dr. Rama Ayash is a medical advisor, senior lecturer, and scientific researcher specializing in clinical biochemistry, diabetes research, and molecular mechanisms of β-cell apoptosis. Her primary research focuses on the pathophysiological role of cytokines and death receptors in glucose dysregulation and prediabetes, with particular emphasis on the therapeutic effects of DPP4 inhibitors such as sitagliptin. Her recent publications include groundbreaking studies in Scientific Reports, BMC Endocrine Disorders, and the European Journal of Pharmacology, exploring inflammatory cytokine modulation, apoptotic biomarkers (FAS, TNFR1, TRAIL-R2), and their relationship to β-cell dysfunction. Dr. Rama Ayash’s research contributions advance understanding of early diabetic mechanisms, aiding in the development of targeted therapeutic strategies to preserve pancreatic function. She has also supervised diverse clinical and molecular research projects in cardiovascular pharmacology, endocrine biomarkers, and celiac disease diagnostics, demonstrating her interdisciplinary expertise. Her work integrates clinical biochemistry, molecular diagnostics, and translational medicine, contributing to the growing field of preventive and precision diabetology. Dr. Rama Ayash has been an active conference speaker and scientific presenter, sharing insights on cardio-renal pharmacology, metabolic pathways, and biomarker discovery. Her continuing research endeavors aim to bridge laboratory findings with clinical outcomes to enhance diagnostic accuracy and therapeutic efficacy in metabolic diseases.

Profiles: Google Scholar | ORCID

Featured Publications

• Ayash, R., Kabalan, Y., & Chamaa, S. (2025). Exploring the predictive potentials of IL-1β and TNFR1 in atherogenic risk in prediabetes. Scientific Reports, 15(1), 37369. https://doi.org/10.1038/s41598-025-37369

• Ayash, R., Kabalan, Y., & Chamaa, S. (2025). Association of soluble apoptotic biomarkers (FAS, TNFR1 and TRAIL-R2) with β-cell dysfunction in early glucose dysregulation. BMC Endocrine Disorders, 25(1), 218. https://doi.org/10.1186/s12902-025-0218

• Ayash, R., Kabalan, Y., & Chamaa, S. (2025). Sitagliptin reduces cytokine-induced β-cell apoptosis in prediabetes: A six-month interventional study. European Journal of Pharmacology, 177708. https://doi.org/10.1016/j.ejphar.2025.177708

Xiaowen Mao | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Assist. Prof. Dr. Xiaowen Mao | Medicine and Health Sciences | Best Researcher Award

University of Macau | Macau

Dr. Xiaowen Mao, M.D., Ph.D., is an Assistant Professor at the State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, where she leads translational research on cancer biology, immunotherapy, and tumor microenvironment modulation. She earned her Ph.D. in Biomedical Sciences from the University of Hong Kong and her B.Sc. in Clinical Medicine from Shanghai Jiao Tong University, China. Her research focuses on extracellular vesicles, immune homeostasis, metabolic reprogramming in tumors, and hepatocellular carcinoma metastasis, integrating molecular, cellular, and translational approaches. Dr. Xiaowen Mao has led several high-impact projects as principal investigator, funded by the Health and Medical Research Fund, National Natural Science Foundation Young Scientist Fund, and FDCT Innovation and Technology Promotion. Her significant contributions include the development of broadly potent neutralizing antibodies targeting Nidogen 1 to inhibit tumor growth, elucidation of extracellular vesicle-mediated metabolic reprogramming in tumors, and advances in dendritic cell vaccine strategies. She holds a U.S. patent on Nidogen 1 as a diagnostic and therapeutic target for hepatocellular carcinoma, serves as Guest Editor for Frontiers in Endocrinology, and is an ad-hoc reviewer for multiple high-impact journals. According to Scopus, she has 31 publications, 1,114 citations by 1,010 documents, and an h-index of 20. Dr. Xiaowen Mao’s work bridges fundamental research and clinical translation, delivering innovative therapies and advancing precision medicine in oncology, while demonstrating a profound impact on cancer biology, immunotherapy, and translational research.

Profile: Scopus

Featured Publications

  • Xue, T. M., Yeung, C. L. S., Mao, X. W., Tey, S. K., Lo, K. W., Tang, H. N., Yun, J. P., & Yam, J. W. P. (2025). Development of a broadly potent neutralizing antibody targeting Nidogen 1 effectively inhibits cancer growth and metastasis in preclinical tumor models. Journal of Translational Internal Medicine. https://doi.org/10.1515/jtim-2025-0008

  • Xia, L., Li, C. G., Zhao, J., Sun, Q. C., & Mao, X. W.* (2025). Rebalancing immune homeostasis in combating disease: The impact of medicine food homology plants and gut microbiome. Phytomedicine, 136, 156150. https://doi.org/10.1016/j.phymed.2025.156150

  • Chen, Z., Yam, J. W. P., & Mao, X. W.* (2024). The multifaceted roles of small extracellular vesicles in metabolic reprogramming in the tumor microenvironments. Proteomics, e2300021. https://doi.org/10.1002/pmic.202300021

  • Lee, K. W., Yam, J. W. P., & Mao, X. W.* (2023). Dendritic cell vaccines: A shift from conventional approach to new generations. Cells, 12(2147). https://doi.org/10.3390/cells12172147

  • Li, S., Delvecchio, M., Ramkumar, K., Mao, X. W., Sun, X. D., & Guo, S. Z. (2023). Editorial: Clinical and genetic determinants of diabetes and complications. Frontiers in Endocrinology.

Haifang Du | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Dr. Haifang Du | Medicine and Health Sciences | Best Researcher Award

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine | China

Dr. Haifang Du is an Assistant Researcher at the Second Affiliated Hospital of Guangzhou University of Chinese Medicine and a researcher at the Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangzhou, China, specializing in targeted drug delivery, exosome technology, and natural product-based cancer therapy. She earned her Ph.D. in Biochemistry and Molecular Biology from the University of Chinese Academy of Sciences in 2019 and completed a postdoctoral fellowship between 2021 and 2023, focusing on advanced precision therapeutics. Previously, she managed research and development projects in the biotechnology sector from 2019 to 2020. Dr. Haifang Du has led six research projects, including three national and provincial initiatives, and continues to explore molecular strategies for bladder cancer, colon cancer, and rheumatoid arthritis therapy. Her scholarly output includes 13 Scopus-indexed publications, with a total of 54 citations and an h-index of 4, six of which she authored as the first or corresponding author. She has three patents under process related to exosome-mediated drug delivery systems. Among her notable works are Exosome-mediated delivery of natural compounds for cancer therapy (Journal of Controlled Release, 2021, cited by 32 articles), Targeted exosome-based therapeutics in oncology (Theranostics, 2022, cited by 24 articles), and Natural product-based immunometabolic interventions in cancer therapy (Frontiers in Pharmacology, 2023, cited by 18 articles). Her research excellence earned her the Hunan Provincial TCM Science and Technology Third Prize (2023). Through her continuous contributions to translational medicine, Dr. Haifang Du is advancing precision drug delivery, enhancing therapeutic efficacy, and promoting the integration of traditional medicine with modern biomedical science to achieve impactful innovation in healthcare.

Profile: Scopus

Featured Publications

  • Du, H., Yu, Y., Yan, X., & Zhang, P. (2025). Identification of chemical constituents, absorbed prototype components, and quality control of Traditional Chinese Medicine formula B granules. Journal of Pharmaceutical and Biomedical Analysis, 268, 117176. https://doi.org/10.1016/j.jpba.2025.117176

  • Huang, X., Wang, X., He, Z., Huang, Y., Hu, B., Chen, W., & Du, H. (2025). Mechanisms, clinical trials, and new treatments for BCG‐unresponsive in nonmuscle invasive bladder cancer. Cancer Medicine, 14(18). https://doi.org/10.1002/cam4.71243

  • Chen, Z., Guo, X., Wu, S., Wang, M., Wu, J., Du, H., Liang, H., Huang, R., & Huang, Q. (2025). Huayu Tongbi formula attenuates rheumatoid arthritis by inhibiting the HIF1A/VEGFA/ANGPT axis and suppressing angiogenesis. Phytomedicine, 139, 156479. https://doi.org/10.1016/j.phymed.2025.156479

Sahar Issa | Health Professions | Best Researcher Award

Published on by Forensic Scientist

Prof. Dr. Sahar Issa | Health Professions | Best Researcher Award

Faculty of medicine, Alexandria University | Egypt

Dr. Sahar Issa, is a distinguished Professor of Forensic Medicine, Clinical Toxicology, and Medical Ethics at the Faculty of Medicine, University of Alexandria, Egypt. She earned her Ph.D. in Forensic Medicine and Clinical Toxicology from Alexandria University, following an M.Sc. in Forensic Medicine & Clinical Toxicology and a Diploma in Public Health specializing in Vector Control and Pesticide Residues Toxicities, alongside her MBChB in Medicine and Surgery. Over her extensive academic career, Dr. Sahar Issa has combined rigorous teaching with cutting-edge research in forensic medicine, toxicology, and medical ethics, contributing to enhanced clinical and forensic practices. Her research interests include toxicological analysis, forensic pathology, sex determination using skeletal traits, and the assessment of chemical and microbial hazards. She has published several influential works, including her book Forensic Toxicology: Poisoning in the Modern World (IntechOpen, 2019) and Microbial Witness: Unraveling Mysteries with Forensic Microbiomes (IntechOpen, 2023). Her peer-reviewed articles cover a wide range of topics such as fentanyl and ketamine effects on liver biochemistry (Toxicology, 2003), forensic toxicology of suicidal and accidental poisonings (Egyptian Journal of Forensic Sciences, 2016), and postmortem trace element analysis (J Forensic Leg Med, 2022), with many of her studies widely cited for their clinical and forensic relevance. Recognized for her contributions to education, toxicology consultation, and public health, Dr. Sahar Issa exemplifies excellence in research, bridging laboratory insights with practical forensic applications and mentoring the next generation of forensic scientists globally.

Profile: Google Scholar | ORCID | LinkedIn

Featured Publications

Hafez, E. M., Issa, S. Y., Ai-Mazroua, M. K., Ibrahim, K. T., & Rahman, S. M. A. (2016). The neonicotinoid insecticide imidacloprid: A male reproductive system toxicity inducer-human and experimental study.

Hafez, M. E., Issa, Y. S., & Abdel Rahman, M. S. (2015). Parenchymatous toxicity of tramadol: Histopathological and biochemical study. Journal of Alcohol and Drug Dependence, 3(5), 225.

Issa, S. Y., Khanfour, A. A., & Kharoshah, M. (2016). A model for stature estimation and sex prediction using percutaneous ulnar and radial lengths in autopsied adult Egyptians. Egyptian Journal of Forensic Sciences, 6(2), 84–89.

Ibrahim, S. Y. (2016). Determination of heavy metals and other toxic ingredients in henna (Lawsonia inermis). Journal of Environmental & Analytical Toxicology, 6(3), 9.

Cebolla, S. G., [et al.]. (2018). Fully automated forensic routine dried blood spot screening for workplace testing. Journal of Analytical Toxicology, 43(2), 1–11.

Issa, S. Y., Hafez, E. M., El-Banna, A. S., Abdel Rahman, S. M., AlMazroua, M. K., … [et al.]. (2018). Baclofen systemic toxicity: Experimental histopathological and biochemical study. Human & Experimental Toxicology, 37(4), 431–441.

Zagloul, N. M., Farghaly, R. M., ELKhatib, H., Issa, S. Y., & El-Zoghby, S. M. (2022). Technology facilitated sexual violence: A comparative study between working and non-working females in Egypt before and during the COVID-19 pandemic. Egyptian Journal of Forensic Sciences, 12(1), 21.

Alalawi, S., Issa, S. T., Takshe, A. A., & ElBarazi, I. (2022). A review of the environmental implications of the COVID-19 pandemic in the United Arab Emirates. Environmental Challenges, 8, 100561.

Eddine, N. N., Noisel, N., Dieme, D., Asmar, M. K., Issa, S. T., & Bouchard, M. (2022). Multi-matrix biomonitoring approach to assess exposure to metals and trace elements in the Lebanese population and associations with drinking water consumption. Environmental Research, 214, 113982.

Xiaoling Ma | Medicine | Best Researcher Award

Published on by Forensic Scientist

Prof. Xiaoling Ma | Medicine | Best Researcher Award

Chief physician | The first hospital of Lanzhou university | China

Dr. Xiaoling Ma is a distinguished Chief Physician and Associate Professor, currently serving as the Director of the Reproductive Medicine Center at The First Hospital of Lanzhou University. With over two decades of experience in reproductive medicine, she has made significant contributions to the advancement of assisted reproductive technology (ART). Dr. Ma is a nationally recognized expert in ART management and holds key positions in several prestigious reproductive medicine organizations in China. Her expertise encompasses reproductive endocrinology, fertility preservation, and genetic screening technologies.

Profile👤

Scopus

Strengths for the Awards✨

✅ Extensive Research Contributions: Xiaoling Ma has published over 30 articles in SCI and core Chinese journals, indicating a strong research output. Recent publications in Biomedicine & Pharmacotherapy, Reproductive Sciences, and BMC Medical Genomics highlight her contributions to reproductive medicine.

✅ Leading Research and Innovation: She has led multiple national and provincial research projects, including studies on reproductive genetics, fertility preservation, and endometriosis mechanisms.

✅ Academic and Professional Influence: As a chief physician, associate professor, and director of the Reproductive Medicine Center, her influence extends to clinical practice, academic mentorship, and policy advisory roles.

✅ Editorial and Professional Leadership: Serving as the Chinese editor for Human Reproduction Update and holding key roles in reproductive medicine associations in China demonstrate her leadership in the field.

🎓 Education

Dr. Xiaoling Ma obtained her Master’s degree in Medicine from a renowned Chinese institution. She has pursued extensive postgraduate training and specialized programs in reproductive medicine, refining her knowledge in assisted reproductive technology, reproductive endocrinology, and genetic screening. Her continuous pursuit of academic excellence has positioned her as a leading educator and mentor in reproductive healthcare.

💼 Experience

With a distinguished career spanning over 20 years, Dr. Ma has been instrumental in pioneering and implementing ART techniques. She has successfully led numerous national and provincial medical projects in China, focusing on fertility evaluation, genetic screening, and reproductive health. In addition to her clinical practice, she plays a pivotal role in policy-making and regulatory aspects of reproductive medicine, ensuring the ethical implementation of ART procedures. As an educator, she has trained and mentored countless physicians, enhancing the field of reproductive medicine across China.

🔬 Research Interests On Medicine

Dr. Ma’s research is dedicated to three-level prevention and control of birth defects, fertility preservation in cancer patients, and the application of genetic screening in reproductive health. She explores the mechanisms behind endometriosis, recurrent pregnancy loss, and infertility, aiming to develop innovative treatment protocols. Her contributions to preimplantation genetic testing (PGT) and reproductive immunology have significantly influenced reproductive healthcare in China and beyond.

🏆 Awards and Recognitions

Dr. Ma has been recognized for her outstanding contributions to reproductive medicine and has received multiple accolades at the national and provincial levels. She is an esteemed member of leading reproductive medicine societies and has played a crucial role in shaping policies related to ART in China. She has also been actively involved in national academic conferences, furthering research and clinical advancements in reproductive health.

📚 Publications

Dr. Ma has published over 30 research articles in SCI-indexed and Chinese core journals. Below are some of her notable publications:

  1. Guan, D., Sun, W., Gao, M., Chen, Z., & Ma, X. (2024). Immunologic insights in recurrent spontaneous abortion: Molecular mechanisms and therapeutic interventions. Biomedicine & Pharmacotherapy, 177, p.117082. [Cited by articles]
  2. Liu, L., Liu, Y., Tian, Y., Cao, Y., Wang, T., Mi, S., Yang, R., Liu, S., Ma, X., & Wang, J. (2024). Identification of differentially expressed mRNAs and lncRNAs contributes to elucidation of underlying pathogenesis and therapeutic strategy of recurrent implantation failure. Reproductive Sciences, pp.1-14. [Cited by articles]
  3. Wang, T., Zhang, L., Gao, W., Liu, Y., Yue, F., Ma, X., & Liu, L. (2024). Transcriptome-wide N6-methyladenosine modification profiling of long non-coding RNAs in patients with recurrent implantation failure. BMC Medical Genomics, 17(1), p.251. [Cited by articles]
  4. Guan, D., Zhao, L., Shi, X., Ma, X., & Chen, Z. (2023). Copper in cancer: from pathogenesis to therapy. Biomedicine & Pharmacotherapy, 163, p.114791. [Cited by articles]

🔚 Conclusion

Dr. Xiaoling Ma is a pioneering figure in reproductive medicine, dedicated to advancing ART and genetic screening technologies. Her extensive clinical expertise, innovative research, and leadership in reproductive medicine make her a highly respected figure in her field. Through her work, she continues to impact countless lives, improving fertility treatments and reproductive healthcare policies. Her commitment to teaching, research, and patient care ensures a lasting legacy in reproductive medicine.

Hyung-Youl Park | Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Assist. Prof. Dr. Hyung-Youl Park | Health Sciences | Best Researcher Award

Assistant Professor | Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea | South Korea 

Dr. Hyung-Youl Park is a Clinical Assistant Professor in the Department of Orthopedic Surgery at Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea. With a focus on spinal cord injuries, disc degeneration, adult spinal deformity, minimally invasive surgery, and osteoporosis, Dr. Park has established himself as a leading figure in both clinical and academic orthopedic surgery. His dedication to improving spinal health is evident in his extensive research, teaching, and clinical expertise.

Profile

Orcid

Strenghts for the Awards

  • Prolific Research Output:
    Dr. Hyung-Youl Park has published extensively, with 72 research articles, including 50 high-impact works in prestigious journals like the European Spine Journal, Diagnostics, World Neurosurgery, and Clinical Orthopaedics and Related Research. His contributions reflect a consistent focus on advancing orthopedic surgery, spinal diseases, and geriatric spinal care.
  • Diverse and Impactful Research Areas:
    His research spans critical topics such as:

    • Risk factors for mechanical complications in spinal surgeries.
    • Pathophysiology and treatment of Kummell’s Disease.
    • Effects of telemedicine on medical staff post-COVID-19.
    • Innovations in bone regeneration and biomaterials.
    • Geriatric spinal fusion and osteoporosis treatment strategies.
    • Surgical management of spinal metastases and deformities.

    These studies showcase clinical relevance and translational impact on improving patient outcomes, particularly in geriatric and oncology-related spinal care.

  • Collaboration and Leadership:
    Dr. Park has co-authored with notable experts like Young-Hoon Kim and Kee-Yong Ha, reflecting his active collaboration in multidisciplinary teams. His involvement in pivotal studies, such as surgical risk factors, spinal imaging, and regenerative medicine, indicates leadership in shaping clinical practices.
  • High-Impact Publications:
    Many of his works are published in journals indexed in Web of Science and Scopus, with notable DOI-linked contributions that enhance global accessibility. His study on telemedicine satisfaction post-pandemic (Telemedicine and e-Health, 2024) and innovative use of recombinant human BMP-2 (Bioengineering, 2023) demonstrate cutting-edge advancements.
  • Clinical Relevance and Recognition:
    Dr. Park’s research addresses real-world challenges, such as post-surgical complications, lumbar stenosis, and adjacent segment degeneration. His findings offer actionable insights for surgical decision-making and patient care optimization.

Education 🎓

Dr. Park holds an impressive academic background:

  • Ph.D. in Orthopedic Surgery (2022), The Catholic University Graduate School, Seoul, Korea.
    • Dissertation: “Are the Choice of Frame and Intraoperative Patient Positioning Associated with Radiologic and Clinical Outcomes in Long-Instrumented Lumbar Fusion for Adult Spinal Deformity?”
  • M.D. (2012), The Catholic University, College of Medicine, Seoul, Korea.

His postgraduate training includes internships, residency, and fellowships at renowned hospitals within the Catholic Medical Center in Korea.

Experience 🏥

Dr. Park’s professional journey spans over a decade of clinical expertise:

  • Clinical Assistant Professor (2020 – Present): Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea.
  • Clinical Fellow (2017–2020): Department of Orthopedic Surgery at Seoul and Eunpyeong St. Mary’s Hospitals.
  • Orthopedic Resident (2013–2017): Seoul St. Mary’s Hospital, Catholic Medical Center, Seoul, Korea.

He actively teaches medical students and residents and has played a pivotal role in weekly spine disorder reviews and conferences.

Research Interests 🔬

Dr. Park’s primary research interests include:

  • Spinal cord injury and disc degeneration.
  • Adult spinal deformity and minimally invasive spine surgery.
  • Osteoporosis and its effects on spinal health.

His research integrates basic science with clinical applications to improve patient outcomes in spine surgery.

Awards and Recognitions 🏆

Dr. Park’s work has earned numerous accolades:

  • Young Investigator Award, Korean Society of Spinal Surgery (2023).
  • Best Investigator Award, Department of Orthopedic Surgery, The Catholic University of Korea (2022).
  • Oral Presentation Awards for innovative research in osteoporosis and spinal tumors at multiple national and international congresses (2016–2021).
  • Nomination for Hibbs Award, Scoliosis Research Society (2017).

These honors reflect his commitment to advancing orthopedic surgery through groundbreaking research.

Publications 📚

Dr. Hyung-Youl Park has authored several impactful articles in high-ranking journals:

  1. “Risk factors for mechanical complications after fusion extension surgery for lumbar adjacent segment disease”
    • Authors: Kim, Young-Hoon; Ha, Kee-Yong; Ahn, Joonghyun; Park, Hyung-Youl; Chang, Dong-Gune; Lim, Jae-Hak; Kim, Sang-Il
    • Journal: European Spine Journal
    • DOI: 10.1007/S00586-023-07880-5
  2. “Understanding Kummell’s Disease: Definition, Diagnosis, Pathophysiology, and Treatment”
    • Authors: Young-Il Ko; Myung-Sup Ko; Chungwon Bang; Hyung-Youl Park; Sang-Il Kim; Young-Hoon Kim
    • Journal: Journal of Korean Society of Spine Surgery
    • DOI: 10.4184/jkss.2024.31.1.23
  3. “Sagittal Realignment Following Decompression for Lumbar Spinal Stenosis in Elderly Patients: A Comprehensive EOS Imaging Analysis”
  4. “Satisfaction Survey of Medical Staff for Telemedicine after the COVID-19 Pandemic”
    • Authors: Seung Eun Jung; Young-Mi Kwon; Soon-Yong Kwon; Young-Hoon Kim; Hyung-Youl Park
    • Journal: Telemedicine and e-Health
    • DOI: 10.1089/tmj.2024.0142
  5. “The Effects of Longer Use of Teriparatide on Clinical and Radiographic Outcomes after Spinal Fusion in Geriatric Patients”
    • Authors: Young-Hoon Kim; Kee-Yong Ha; Hyun W. Bae; Hyung-Youl Park; Young-Il Ko; Myung-Sup Ko; Sang-Il Kim
    • Journal: Medicina
    • DOI: 10.3390/medicina60060946
  1. “Effects of bone cement augmentation for uppermost instrumented vertebra on adjacent disc segment degeneration in lumbar fusions”
    • Authors: Lee, Jae-Won; Kim, Hun-Chul; Kim, Sang-Il; Min, Hyung-Ki; Ha, Kee-Yong; Park, Hyung-Youl; Cho, Chang-Hee; Sung, Hoon-Seok; Lim, Jae-Hak; Kim, Young-Hoon
    • Journal: World Neurosurgery
    • DOI: 10.1016/J.WNEU.2022.11.014
  2. “Junctional Failures at Both Ends After Long Fusion Arthrodesis Stopping at L5: Incidences and Risk Factors”
    • Authors: Kim, Y.-H.; Ha, K.-Y.; Park, H.-Y.; Ko, M.-S.; Ko, Y.-I.; Sin, K.-J.; Kim, S.-I
    • Journal: World Neurosurgery
    • DOI: 10.1016/j.wneu.2023.09.063
  3. “Predictive factors for conversion from conservative to surgical treatment in osteoporotic thoracolumbar compression fractures”
    • Authors: Sung, Hoon-Seok; Kim, Sang-Il; Park, Hyung-Youl; Ko, Myung-Sup; Lee, Jeong-Han; Kim, Young-Hoon
    • Journal: European Spine Journal
    • DOI: 10.1007/S00586-023-07864-5
  4. “Risk Factors for Conversion to Open Spinal Surgery after Percutaneous Epidural Neuroplasty”
    • Authors: Young-Hoon Kim; Sang-Il Kim; Jun-Seok Lee; Hyung-Youl Park
    • Journal: Journal of Korean Society of Spine Surgery
    • DOI: 10.4184/jkss.2023.30.1.18
  5. “When Should Spinal Surgery Be Considered for Spinal Metastasis from Non-Small Cell Lung Cancer?”
    • Authors: Hyung-Youl Park; Kee-Yong Ha; Sang-Il Kim; Yeon-Sil Kim; Yongwon Joh; Young-Hoon Kim
    • Journal: Journal of Clinical Medicine
    • DOI: 10.3390/jcm12144683

Conclusion

Dr. Hyung-Youl Park is a distinguished orthopedic surgeon, educator, and researcher dedicated to advancing spine health through innovative clinical practices and impactful research. His achievements reflect a blend of clinical expertise, academic excellence, and a passion for improving patient outcomes.